Exercise may be doing far more than changing what you see in the mirror. Research into trained older muscle suggests long-term physical activity may help preserve parts of the molecular machinery tied to energy, adaptation and resilience.
Fitness is usually measured by strength, endurance or appearance, but aging also happens beneath the surface. A Nature Aging study found meaningful molecular differences between typical older muscle and muscle from trained older adults. This episode of Builder’s Creed looks at what those findings could mean for energy, resilience and staying physically capable over time.
Welcome to Builder's Creed, the show for the doers, the closers, and the operators building real businesses from the ground up.
Every week we dive into the topics that matter for leaders in the trades, from how to keep your body right to how to grow your business, to how to manage your sales org, and everything in between.
This isn't theory, it's the playbook straight from the people living it.
If you're building something of your own, you're in the right place.
Let's get into it.
So let's come back to the hook.
AI screened more than 800,000 molecules.
It found three novel synolytic drug candidates.
Those candidates target senescent cells, damaged cells linked to aging, inflammation, cancer, Alzheimer's, eyesight loss, mobility issues, and other age-related conditions.
And the process points to something bigger than one study.
It shows us a new model of discovery, less blind searching, more intelligent filtering, lower cost, faster iteration, better shots on goal.
That is the real value proposition.
Not that AI has solved aging, it has not.
Not that these are ready-to-use drugs, they are not.
The value is that AI is starting to reveal options humans could not see fast enough.
And for builders, that is the lesson.
The future does not belong to the people who work hardest inside broken systems.
It belongs to the people who rebuild the system.
Drug discovery has been slow, expensive, and full of failure for decades.
AI does not remove the hard parts, but it changes where the search begins, and sometimes that is enough to change everything.
I'm Justin Brack, and that's a wrap on this one.
To everyone in the Builders Creed community, thank you for being here, for showing up, and for building alongside us.
None of this works without you.
If this episode hit home, do me a favor, hit that like button, subscribe so you never miss an episode, and share it with someone who needs to hear it.
Until next time, keep building.
AI screened more than 800,000 molecules in weeks.
A human team doing this the old way could spend decades chasing that same chemical space.
And here's the part that should stop every builder in their tracks.
The AI did not just make a prediction, it found three new drug candidates that target one of the most important drivers of aging, senescent cells.
These are damaged cells that stop dividing but refuse to die.
They sit in the body, leak inflammatory signals, and stress nearby healthy cells.
They have also been linked to some of the most expensive, painful, and destructive age-related diseases we know.
This is the frontier.
AI is no longer just writing emails, making images, or helping companies automate customer service.
AI is starting to search biology itself, and in this case, it found anti-aging drug candidates humans had missed.
Today we are talking about what happens when AI becomes a discovery engine for medicine.
And if this works, it could reshape how we treat aging, chronic disease, and the entire drug discovery model.
Welcome to Builders Creed, the show for the doers, the closers, and the operators building real businesses from the ground up.
Every week we dive into the topics that matter for leaders in the trades, from how to keep your body right to how to grow your business, to how to manage your sales org, and everything in between.
This isn't theory, it's the playbook, straight from the people living it.
If you're building something of your own, you're in the right place.
Let's get into it.
I'm Justin Brach.
Today's episode is about builders operating at the edge of biology, AI, and medicine.
People who are looking at one of the most broken systems in the world, drug discovery, and asking a better question.
What if the next breakthrough is not hidden in one molecule?
What if it is hidden in a pattern?
For decades, drug discovery has worked like this.
Pick a target, search for a molecule, test it, fail, test again, fail again, spend years, spend fortunes.
Hope something survives long enough to reach patients.
That system has produced miracles.
We should respect it, but it is also brutally slow, expensive, and wasteful.
So the builder question is simple.
Can AI compress the search, scan what humans cannot, and find useful signals inside millions of biological and chemical possibilities?
In the case of synolytic drugs, the answer may be yes.
To understand why this matters, we need to talk about senescent cells.
These are sometimes called zombie cells.
A normal, healthy cell divides, does its job, and eventually dies when it is damaged or no longer needed, but a senescent cell is different.
It is alive, but it no longer divides.
In some cases, that is protective.
If a cell has DNA damage, stopping it from dividing can help prevent cancer.
So senescence is not automatically bad.
It is part of the body's defense system.
The problem starts when these cells accumulate.
As we age, more cells become senescent.
They build up in tissues.
And instead of staying quiet, they start secreting inflammatory signals.
And they are slowing down the entire operation around them.
That is why researchers care about senescent cells.
They are linked to inflammation, tissue dysfunction, and age-related disease.
This does not mean senescent cells are the only cause of aging.
Aging is a network failure, but senescent cells are one of the major failure points.
So the opportunity is obvious.
What if we could selectively remove these cells?
That is where senolytics come in.
Senolytics are drugs designed to selectively kill senescent cells.
The idea is simple.
If zombie cells are damaging the tissue environment, remove them.
In lab studies, removing senescent cells has shown promise across multiple age-related conditions.
That is why synolytics have become one of the most interesting areas in longevity science.
But there is a problem.
Finding good synolytics is hard.
You need compounds that are strong enough to kill senescent cells, but selective enough to leave healthy cells alone.
That is a narrow target.
Too weak and the drug does nothing, too aggressive and it becomes toxic.
This is why many synolytic candidates have limitations, and the field needs better compounds.
This is exactly where AI enters the story.
Researchers from integrated biosciences, MIT, and Harvard approached this problem with a builder mindset.
Instead of manually testing everything, they built a system.
First, they experimentally screened 2,352 compounds to see which ones had synolytic activity.
That became the training data.
Then they trained graph neural networks, a type of AI model that can learn from molecular structure to predict which compounds might act as synolytics.
Then they pointed that model at a chemical space of more than 800,000 molecules.
That is the key.
Humans cannot reasonably test 800,000 molecules one by one in the lab without massive cost, time, and infrastructure.
AI can narrow the field, it prioritizes where biology should look, it turns an impossible search into a focused search.
And in this case, the AI identified three highly selective and potent synolytic compounds.
These compounds showed drug-like properties, had favorable toxicity profiles in early testing, and appeared to target senescent cells across different models.
And one compound tested in aged mice reduced senescent cell burden and lowered the expression of senescence associated genes in the kidneys.
That does not mean we have an approved anti-aging drug.
This is still early, but it is a serious signal because the model did what builders care about most.
It reduced waste, compressed time, and found leverage.
Now let's talk about the cost story.
In related machine learning work on synolytics, researchers showed that AI could reduce screening costs by several hundredfold.
That is where the 600 times cheaper idea becomes powerful.
Because drug discovery is not just a science problem, it is an economics problem.
If testing a massive chemical library costs too much, fewer experiments happen.
If fewer experiments happen, fewer shots are taken.
If fewer shots are taken, fewer drugs reach patients.
AI changes the math.
It allows researchers to explore a massive chemical universe digitally before spending money in the lab.
Instead of buying and testing thousands or millions of compounds blindly, teams can rank candidates first.
That means less waste, more focused experiments.
This matters especially for aging and chronic disease because these are complex systems.
If we use old methods alone, the search is too slow.
AI gives researchers a way to move faster without pretending biology is simple.
And that distinction matters.
The headline says AI found drugs humans missed, but that does not mean humans failed.
It means humans were operating with the wrong tools for the size of the problem.
Imagine walking into a warehouse with 800,000 locked boxes.
Three of them contain something valuable.
You could open every box manually, but that might take years.
Or you could build a scanner that tells you which boxes are most likely to matter.
That is what AI did here.
The molecules were not invisible, they were just buried inside a chemical universe too large for traditional search.
This is the builder lesson.
Sometimes the breakthrough is not creating a new thing from scratch, but building a better search system.
That is what AI is becoming in medicine.
This is why the next generation of biotech companies will not look like old pharmaceutical companies.
They will look like hybrid systems.
Part biology lab, part software company.
The winners will not simply have the best molecule.
They will have the best discovery system.
Now we need to be careful with the phrase anti-aging because the internet has ruined that term.
Anti-aging gets used to sell creams, supplements, shortcuts, and fantasy.
That is not what we are talking about here.
We are talking about uh the biology of aging, the mechanisms that increase the risk of disease as we get older.
Senescent cells are one of those mechanisms.
If senolytics can safely remove harmful senescent cells, they could support healthier aging.
That could matter for diseases where senescent cells play a role.
Cancer, Alzheimer's, fibrosis, osteoarthritis, metabolic disease, vision loss, mobility decline.
The body is a system.
Aging is what happens when that system accumulates damage faster than it can repair, clear, or adapt.
Senalytics are one possible intervention in that system.
AI is the tool that helps discover better versions of those interventions.
That is the actual story.
Not AI found the cure for aging.
The real story is sharper.
AI found new candidates that may help target one aging-related failure mode.
Now here's where we stay grounded.
These compounds are not approved anti-aging drugs.
They are not something people should go buy, copy, or experiment with.
This is early stage drug discovery.
A molecule can look promising in a model and still fail in humans.
That is normal.
Biology is ruthless.
A compound may not absorb well, it may have side effects or fail when tested in real patients.
That is why builders in biotech cannot be hype merchants.
They need discipline.
Models are not medicines, predictions are not outcomes, candidates are not cures.
The AI gives us a better starting point.
The lab still has to prove it.
The clinic still has to prove it.
Patients still have to be protected.
This is the line between serious longevity science and reckless longevity marketing.
Serious Science says here is a promising mechanism and the data.
Here is what we know.
Here is what we do not know.
Now let's validate it.
Hype says AI found anti-aging drugs, so the problem is solved.
That is not the Builder's Creed standard.
Builders respect the gap between a prototype and a finished system.
And in medicine, that gap is human life.
Here's the framework I want you to remember.
AI drug discovery is not about replacing scientists.
It is about upgrading the search process.
There are four steps.
First, define the biological problem.
In this case, senescent cells.
Damage cells that stop dividing, build up with age, and release inflammatory signals.
Second, create training data.
The researchers screened known compounds and taught the model what synolytic activity looks like.
Third, search the mass of space.
The AI scanned hundreds of thousands of molecules and ranked the most promising candidates.
Fourth, validate in the real world.
Eventually, if justified, human trials.
That is the pattern.
Problem, data, search, validation.
This same framework applies beyond medicine.
In business, you define the bottleneck, you collect the right data, you use systems to identify leverage, then you test in reality.
That is how builders operate.
This story matters because it shows where AI is going.
The first wave of AI helped us generate content.
The next wave is more important.
AI will help us search complex systems, biology, materials, logistics, healthcare, financial risk.
Anywhere the search space is too large for human intuition alone, AI becomes leverage.
That is why this is a builder story.
The future will belong to people who know how to combine domain expertise with intelligent systems.
AI is not the builder.
AI is the leverage.
The builder still decides what is worth building.
That's a wrap on this one.
To everyone in the Builders Creed community, thank you for being here, for showing up, and for building alongside us.
None of this works without you.
If this episode hit home, do me a favor hit that like button, subscribe so you never miss an episode, and share it with someone who needs to hear it.
Until next time, keep building.
EP-16Some AI data centers now draw more power than entire cities, triggering historic events. This episode explores what’s really powering the AI revolution, and why builders, not coders, are the ones determining how fast it actually arrives.
EP-14Biology does not operate one gene or pathway at a time. AI is helping researchers model the interactions between those pieces, creating a new way to explore how cells behave, respond and change before every question reaches the lab.
EP-13Aging touches every system we build on; healthcare, families, businesses, economies. This episode breaks down how AI is turning longevity from something we react to into something we can predict, plan for, and build around.
Resources
